These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 28687231)

  • 21. Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia.
    Sato H; Miyata Y; Inoue H; Tanaka A; Sagara H
    J Investig Allergol Clin Immunol; 2021 Oct; 31(5):459-460. PubMed ID: 33502319
    [No Abstract]   [Full Text] [Related]  

  • 22. Biological treatment is approved for severe eosinophilic asthma.
    Mayor S
    BMJ; 2016 Nov; 355():i6472. PubMed ID: 27908911
    [No Abstract]   [Full Text] [Related]  

  • 23. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia.
    Shimizu Y; Kurosawa M; Sutoh Y; Sutoh E
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):154-155. PubMed ID: 31778113
    [No Abstract]   [Full Text] [Related]  

  • 25. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
    Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N
    Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis.
    Lugogo N; Liu MC; Pavord I; Mitchell PD; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Bel EH
    J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3506-3509.e3. PubMed ID: 34111572
    [No Abstract]   [Full Text] [Related]  

  • 27. Advances in pharmacotherapy of asthma.
    Haahtela T
    Curr Probl Dermatol; 1999; 28():135-52. PubMed ID: 10374061
    [No Abstract]   [Full Text] [Related]  

  • 28. Asthma and other wheezing disorders of childhood.
    Keeley D; McKean M
    Clin Evid; 2003 Jun; (9):287-317. PubMed ID: 15366138
    [No Abstract]   [Full Text] [Related]  

  • 29. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma.
    Yancey SW; Ortega HG; Keene ON; Mayer B; Gunsoy NB; Brightling CE; Bleecker ER; Haldar P; Pavord ID
    J Allergy Clin Immunol; 2017 Apr; 139(4):1167-1175.e2. PubMed ID: 27726946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists.
    McKeage K
    Drugs; 2015 May; 75(7):809-16. PubMed ID: 25895466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma.
    Nixon R; Despiney R; Pfeffer P
    BMJ Case Rep; 2020 Feb; 13(2):. PubMed ID: 32086326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
    Castro M; Bacharier LB
    Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacologic modulation of airway inflammation.
    O'Byrne PM; Gauvreau GM; Wood LJ
    Allergy; 1998; 53(45 Suppl):41-7. PubMed ID: 9788706
    [No Abstract]   [Full Text] [Related]  

  • 37. Reslizumab in the treatment of severe eosinophilic asthma: an update.
    Walsh GM
    Immunotherapy; 2018 Jun; 10(8):695-698. PubMed ID: 29554826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asthma.
    Fanta CH
    N Engl J Med; 2009 Mar; 360(10):1002-14. PubMed ID: 19264689
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
    Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
    Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.